Potent cytotoxic C-11 modified geldanamycin analogues

Area of Science:

• Medicinal Chemistry
• Molecular Biology
• Oncology

Background:

• Heat shock protein 90 (Hsp90) is a crucial target for cancer therapy.
• 17-Allylamino-17-demethoxygeldanamycin (17-AAG) is a known Hsp90 inhibitor with therapeutic potential.
• Developing geldanamycin (GDM) analogues with enhanced properties is critical for improved cancer treatment.

Purpose of the Study:

• To synthesize and evaluate novel C-11 modified geldanamycin (GDM) derivatives.
• To assess the Hsp90 binding affinity and in vitro cytotoxicity of these analogues.
• To identify GDM analogues with superior anti-cancer properties compared to 17-AAG.

Main Methods:

• Synthesis of C-11 modified GDM derivatives (ethers, esters, carbazates, ketones, oximes).
• Measurement of Hsp90 binding affinity for synthesized analogues.
• Assessment of in vitro cytotoxicity against human cancer cell lines.
• Analysis of structure-activity relationships concerning C-11 modifications.

Main Results:

• Bulky C-11 substituents hindered Hsp90 binding, while smaller groups like 11-O-methyl facilitated binding.
• Synthesized analogues exhibited in vitro cytotoxicity against cancer cells.
• Esterification of 17-AAG's 11-OH group abolished Hsp90 binding, with esters acting as prodrugs.
• Several 11-O-methyl-17-alkylaminogeldanamycin analogues demonstrated increased potency compared to 17-AAG.

Conclusions:

• C-11 modification is a viable strategy for developing potent Hsp90 inhibitors.
• 11-O-methyl geldanamycin derivatives represent promising candidates for cancer therapy.
• Optimized geldanamycin analogues offer potential for improved anti-cancer efficacy.